Livongo Health Has Completed an Initial Public Offering

August 8, 2019

Livongo Health, Inc (“Livongo”) announced the closing of an initial public offering of 14.6 million shares of its common stock at a price of $28.00 per share. Total proceeds of $408.5 million will be used for general corporate purposes, including working capital, operating expenses and capital expenditures. The shares began trading on The Nasdaq Global Select Market under the symbol “LVGO” on July 25, 2019. We served as a co-manager on the transaction. The IPO priced at $28.00 per share on July 24, 2019, above the $24.00 – $26.00 range (revised up from $20.00 – $23.00). LVGO most recently closed up 20% since the offer.

Livongo offers a whole person platform that empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention and behavioral health. Livongo pioneered the new category of Applied Health Signals to offer Members clinically-based insights that make it easier to stay healthy. Livongo’s team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions.

Livongo is headquartered in Mountain View, CA and was founded in 2014. Livongo’s investors have included General Catalyst, Humana, Kleiner Perkins, Merck Global Health Innovations, Kinnevik, Zaffre Investments, Echo Health Ventures, Sapphire Ventures, EDBI, M12 and 7wire Ventures.

For more information, please contact:

Jill Frew

Managing Director
(212) 981-6916